Enzyme Engineering

& Industrial Fermentation

Enzymes are widely used as biocatalysts in the production or processing of a wide range of products including food, beverages, animal feeds, detergents, pharmaceuticals and textile products. Naturally occurring enzymes are often unstable or perform sub-optimally when moved from the biological to the industrial sphere.

Therefore, since the advent of protein engineering there have been efforts to improve these enzyme properties, and even to devise enzymes with novel specificities capable of producing types or quantities of metabolites not normally achievable in natural products. Such improvements or changes can often be challenging: enzyme activity depends on specific and highly complex structures, sometimes formed from multiple protein components, and requiring associated factors or metal ions to operate. Frequently, enhancing one desirable property comes at the cost of impairing another.

Mewburn Ellis has a long history of working with our clients in this fast-moving and competitive field. For example, we’ve been involved in protecting the ground-breaking innovations on the serine protease subtilisin (used for example in detergents and in food processing) since 1980s, and in multiple other enzymes in different fields such as brewing, biofuels and biopolymers. The Mewburn team has regularly and successfully defended patents covering our clients’ enzyme technologies at the EPO and assisted them in enforcing those patents before national courts. Engineered enzymes are typically produced in host species such as bacteria, yeasts and filamentous fungi and we also have many years’ experience in dealing with the fermentation technologies used for growing these microorganisms, and recovering the enzymes from them, whether at laboratory or industrial scale.

As more and more powerful computation tools are developed for determining and modelling protein structures, so protein engineers are increasingly able to analyse the structure-function characteristics for rationale design of novel enzymes, which can then be tested in large scale functional screening processes. Once again, our specialised team here is able to assist at our clients with obtaining protection for their intellectual property in the latest bioinformatics innovations in the enzyme space.

Open pages of Green IP Report

Green IP Report

Patents are both a driver and a barometer of innovation

Our report examines the role of patents in making innovative ‘green’ technologies into a reality as well as how the patent landscape can be used to identify opportunities for partnering, collaboration and investment.

We share our enthusiasm and admiration for commercially-focused innovation across a diverse range of technologies, from repurposing carbon dioxide to make protein-rich foods, to the multi-faceted approach to a circular plastics economy. We also discuss the tantalising prospect of AI-mediated renewable energy supply, and the harnessing of battery tech from the EV boom to drive energy efficiency in consumer devices. This report reflects our passion for technology solutions that tackle our shared global challenge.

Download the Report

Read our Blogs

Advanced Therapeutics – European Patent Oppositions

Advanced Therapeutics – European Patent Oppositions

by Anna Mudge

We investigated EPO opposition trends in the cell and gene therapy space across five years (2020-2024), using opposition data from the EPO and a combination of IPC codes and keywords.

Biosynthetic Dyes: The Future of Sustainable Fashion

Biosynthetic Dyes: The Future of Sustainable Fashion

by Isobel Fisher

The fashion industry is a major polluter. While many of us know about the textile waste from fast fashion and the fossil fuels used to transport our clothes, one area that often goes unnoticed is the ...

UPC Weekly - As sure as eggs is eggs …

UPC Weekly - As sure as eggs is eggs …

by Matthew Naylor

2025 Week 42 This week we report on two decisions from the UPC that are totally different, but both important in their own way. The first is a down-in-the-detail first instance case on infringement ...

UPC Weekly - Who counts as an infringer? Court of Appeal clarifies director liability

UPC Weekly - Who counts as an infringer? Court of Appeal clarifies director liability

by Lucy Coe

2025 Week 41 The UPC Court of Appeal’s second ruling on the merits is out in the Philips v. Belkin case. This decision broadens who can be considered an “infringer” beyond those directly performing ...

Five Under Discussed Trends in ADC Innovation

Five Under Discussed Trends in ADC Innovation

by Robert Andrews

What came up when we asked the experts: what's next for antibody-drug conjugates?

Mewburn Ellis Congratulates Prof. Shimon Sakaguchi on Nobel Prize for Treg Cell Discovery

Mewburn Ellis Congratulates Prof. Shimon Sakaguchi on Nobel Prize for Treg Cell Discovery

by Jo Cripps

We are thrilled that Dr Shimon Sakaguchi, distinguished Professor at Osaka University’s Immunology Frontier Research Center, is one of the winners of the Nobel Prize in Physiology or Medicine for the ...

Learn More
Forward Magazines Overlapping 8

Mewburn Ellis

FORWARD MAGAZINE

Mewburn Ellis Forward is a biannual publication that celebrates the best of innovation and exploration. Through its pages we hope to inform and entertain, but also to encourage discussion about the most compelling developments taking place in the scientific and entrepreneurial world. Along the way, we’ll engage with the IP challenges that international organisations face every day.